| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 5 securities · may seek to influence control | ||||||
|
City Therapeutics, Inc.
13D
178782108
|
25.6% |
10/26/2026
Event 10/19/2026
|
||||
| ARCH Venture Fund XII, L.P. | 25.6% | |||||
| ARCH Venture Partners XII, L.P. | 25.6% | |||||
| ARCH Venture Partners XII, LLC | 25.6% | |||||
| Robert Nelsen | 25.6% | |||||
| Keith Crandell | 25.6% | |||||
| Kristina Burow | 25.6% | |||||
| Steven Gillis | 25.6% | |||||
|
Seaport Therapeutics, Inc.
13D
SPTX · 81221K108
|
11.9% |
5/6/2026
Event 5/4/2026
|
||||
| ARCH Venture Fund XII, L.P. | 11.9% | |||||
| ARCH Venture Partners XII, L.P. | 11.9% | |||||
| ARCH Venture Partners XII, LLC | 11.9% | |||||
| Robert Nelsen | 11.9% | |||||
| Keith Crandell | 11.9% | |||||
| Kristina Burow | 11.9% | |||||
| Steven Gillis | 11.9% | |||||
|
Neumora Therapeutics, Inc.
13D/A
NMRA · 640979100
|
18.7% |
4/1/2026
Event 3/30/2026
|
||||
| ARCH Venture Fund VII, L.P. | 18.6% | |||||
| ARCH Venture Fund VIII Overage, L.P. | 18.6% | |||||
| ARCH Venture Fund X, L.P. | 18.6% | |||||
| ARCH Venture Fund X Overage, L.P. | 18.6% | |||||
| ARCH Venture Fund XII, L.P. | 18.6% | |||||
| ARCH Venture Partners VII, L.P. | 18.6% | |||||
| ARCH Venture Partners X, L.P. | 18.6% | |||||
| ARCH Venture Partners X Overage, L.P. | 18.6% | |||||
| ARCH Venture Partners XII, L.P. | 18.6% | |||||
| ARCH Venture Partners VII, LLC | 18.6% | |||||
| ARCH Venture Partners VIII, LLC | 18.6% | |||||
| ARCH Venture Partners X, LLC | 18.6% | |||||
| ARCH Venture Partners XII, LLC | 18.6% | |||||
| Robert Nelsen | 18.6% | |||||
| Keith Crandell | 18.6% | |||||
| Clinton Bybee | 2.0% | |||||
| Kristina Burow | 18.7% | |||||
| Steven Gillis | 17.3% | |||||
|
Metsera, Inc.
13D/A
MTSR · 59267L107
|
0% |
11/14/2025
Event 11/13/2025
|
||||
| ARCH Venture Fund XII, L.P. | 0% | |||||
| ARCH Venture Fund XIII, L.P. | 0% | |||||
| ARCH Venture Partners XII, L.P. | 0% | |||||
| ARCH Venture Partners XIII, L.P. | 0% | |||||
| ARCH Venture Partners XII, LLC | 0% | |||||
| ARCH Venture Partners XIII, LLC | 0% | |||||
| Robert Nelsen | 0% | |||||
| Keith Crandell | 0% | |||||
| Kristina Burow | 0% | |||||
| Steven Gillis | 0% | |||||
| Paul Berns | 0% | |||||
|
Prime Medicine, Inc.
13D/A
PRME · 74168J101
|
10.4% |
8/11/2025
Event 8/7/2025
|
||||
| ARCH Venture Fund X, L.P. | 10.4% | |||||
| ARCH Venture Fund X Overage, L.P. | 10.4% | |||||
| ARCH Venture Fund XII, L.P. | 10.4% | |||||
| ARCH Venture Partners X, L.P. | 10.4% | |||||
| ARCH Venture Partners X Overage, L.P. | 10.4% | |||||
| ARCH Venture Partners XII, L.P. | 10.4% | |||||
| ARCH Venture Partners X, LLC | 10.4% | |||||
| ARCH Venture Partners XII, LLC | 10.4% | |||||
| Robert Nelsen | 10.4% | |||||
| Keith Crandell | 10.4% | |||||
| Kristina Burow | 10.4% | |||||
| Steven Gillis | 10.4% | |||||
| Schedule 13G · 1 security · passive | ||||||
|
Parabilis Medicines, Inc.
13G
PBLS · 698955101
|
5.3% |
8/14/2026
Event 6/30/2026
|
||||
| ARCH Venture Fund XII, L.P. | 5.3% | |||||
| ARCH Venture Partners XII, L.P. | 5.3% | |||||
| ARCH Venture Partners XII, LLC | 5.3% | |||||
| Robert Nelsen | 5.3% | |||||
| Keith Crandell | 5.3% | |||||
| Kristina Burow | 5.3% | |||||
| Steven Gillis | 5.3% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.